Sofosbuvir / velpatasvir / voxilaprevir (new indication: chronic hepatitis C; adolescents from 12 to < 18 years)

Subject:

• Active Substance: Sofosbuvir / velpatasvir / voxilaprevir
• Name: Vosevi^®
• Therapeutic area: Chronic hepatitis C
• Pharmaceutical company: Gilead Sciences GmbH

Time table:

• Start: 15.10.2021
• Final decision by G-BA: 07.04.2022

Final decision:

• No additional benefit proved